The Therapeutic potential of lentivector-delivered RNAi

Autor: Casey, NP

Many forms of leukaemia are caused by chromosomal translocations, which result in specific and characteristic genomic sequences. Where these sequences are unique to the leukaemic cells, they represent good candidates for targeting by sequencespecific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acfc7a2d9764f8ec7273d0c8fb221fed

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

In vitro re-challenge of CAR T cells.

Autor: Klee CH; Translational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Villatoro A; Translational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Casey NP; Translational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Inderberg EM; Translational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway., Wälchli S; Translational Research Unit, Section of Cellular Therapy, Department of Oncology, Oslo University Hospital, Oslo, Norway. Electronic address: sebastw@rr-research.no.

Publikováno v: Methods in cell biology [Methods Cell Biol] 2024; Vol. 183, pp. 335-353. Date of Electronic Publication: 2023 Sep 15.

ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

Autor: Mensali N; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Köksal H; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Joaquina S; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Wernhoff P; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Casey NP; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Romecin P; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain., Panisello C; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain., Rodriguez R; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Hospital Universitario Central de Asturias, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.; Centro de Investigación Biomédica en Red-Oncología (CIBER-ONC), Instituto de Salud Carlos III, Madrid, Spain., Vimeux L; Université de Paris, Institut Cochin, INSERM, CNRS, Equipe labellisée Ligue Contre le Cancer, F-75014, PARIS, France., Juzeniene A; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Myhre MR; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Fåne A; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Ramírez CC; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital, CSIC, University of Sevilla, CIBER-ONC, 41013, Seville, Spain., Maggadottir SM; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Duru AD; NSU Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA., Georgoudaki AM; NSU Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Grad I; Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Maturana AD; Laboratory of Animal Cell Physiology, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, Japan., Gaudernack G; Department of Cancer Immunology, Oslo University Hospital, Oslo, Norway., Kvalheim G; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Carcaboso AM; SJD Pediatric Cancer Center Barcelona, Institut de Recerca Sant Joan de Deu, Barcelona, 08950, Spain., de Alava E; Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital, CSIC, University of Sevilla, CIBER-ONC, 41013, Seville, Spain.; Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41009, Seville, Spain., Donnadieu E; Université de Paris, Institut Cochin, INSERM, CNRS, Equipe labellisée Ligue Contre le Cancer, F-75014, PARIS, France., Bruland ØS; Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Menendez P; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas (TERAV)-Instituto de Salud Carlos III (ISCIII) (RICORS, RD21/0017/0029), Madrid, Spain.; CIBER-ONC, ISCIII, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain., Inderberg EM; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. elsin@rr-research.no., Wälchli S; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway. sebastw@rr-research.no.

Publikováno v: Nature communications [Nat Commun] 2023 Jun 08; Vol. 14 (1), pp. 3375. Date of Electronic Publication: 2023 Jun 08.

How CAR T Cells Breathe.

Autor: Forcados C; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway., Joaquina S; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway., Casey NP; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway., Caulier B; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.; Center for Cancer Cell Reprogramming (CanCell), Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0372 Oslo, Norway.; Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway., Wälchli S; Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, 0379 Oslo, Norway.

Publikováno v: Cells [Cells] 2022 Apr 25; Vol. 11 (9). Date of Electronic Publication: 2022 Apr 25.